Capital Analysts LLC’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Capital Analysts LLC’s Portfolio PBE Stock Details PBE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$90K	Sell	1,138 -59	-5%	-$4.77K	﹤0.01%	821
2025 Q4	$98K	Buy	1,197 +46	+4%	+$3.56K	﹤0.01%	774
2025 Q3	$80K	Sell	1,151 -564	-33%	-$38.1K	﹤0.01%	786
2025 Q2	$110K	Hold	1,715	–	–	﹤0.01%	647
2025 Q1	$109K	Hold	1,715	–	–	﹤0.01%	625
2024 Q4	$114K	Buy	1,715 +615	+56%	+$42.4K	﹤0.01%	585
2024 Q3	$77K	Hold	1,100	–	–	﹤0.01%	637
2024 Q2	$71K	Buy	1,100 +1,024	+1,347%	+$64.8K	﹤0.01%	640
2024 Q1	$5K	Buy	+76	New	+$4.95K	﹤0.01%	991

Other funds holding PBE

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UCFA

United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

GKWIM

Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return

YIA

YHB Investment Advisors West Hartford, Connecticut $1.56B AUM 27.39% 1-Year Est. Return

Cetera Investment Advisers Schaumburg, Illinois $94B AUM 20.14% 1-Year Est. Return

Capital Analysts LLC's PBE Position: Q1 2026 in Review

Capital Analysts LLC reduced its Invesco Biotechnology & Genome ETF (PBE) stake by 4.9% in Q1 2026, selling an estimated $4.77K and leaving 1,138 shares worth $90K. The position accounts for ﹤0.01% of the portfolio, ranked #821.

Capital Analysts LLC first reported a position in PBE in Q1 2024 and has held it in 9 quarters since. The position peaked at $114K in Q4 2024. 100 funds tracked by Wall St. Rank hold PBE as of Q1 2026.

Capital Analysts LLC held 1,138 shares of Invesco Biotechnology & Genome ETF worth $90K as of Q1 2026.
Capital Analysts LLC sold 59 Invesco Biotechnology & Genome ETF shares in Q1 2026, an estimated $4.77K.
Invesco Biotechnology & Genome ETF made up ﹤0.01% of Capital Analysts LLC's portfolio in Q1 2026, its #821 holding.
Capital Analysts LLC first reported a position in Invesco Biotechnology & Genome ETF in Q1 2024 and has held it in 9 quarters since.
Capital Analysts LLC's Invesco Biotechnology & Genome ETF position peaked at $114K in Q4 2024.
100 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q1 2026.

Based on Capital Analysts LLC's 13F filing for Q1 2026, filed 14 May 2026.